KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) insider Paul K. Audhya sold 8,077 shares of the company's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now directly owns 94,199 shares of the company's stock, valued at $872,282.74. This represents a 7.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
KalVista Pharmaceuticals Trading Down 1.0 %
NASDAQ:KALV opened at $8.96 on Thursday. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.39 and a fifty-two week high of $16.88. The business's 50-day simple moving average is $11.06 and its 200-day simple moving average is $12.01.
KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04. As a group, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.
Institutional Investors Weigh In On KalVista Pharmaceuticals
Urgent: This election is rigged
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
A number of hedge funds and other institutional investors have recently bought and sold shares of KALV. nVerses Capital LLC bought a new position in shares of KalVista Pharmaceuticals during the 2nd quarter worth approximately $25,000. EntryPoint Capital LLC bought a new position in shares of KalVista Pharmaceuticals in the 1st quarter valued at about $92,000. China Universal Asset Management Co. Ltd. increased its stake in shares of KalVista Pharmaceuticals by 67.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company's stock worth $96,000 after purchasing an additional 3,328 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter valued at about $126,000. Finally, SG Americas Securities LLC acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $153,000.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of KalVista Pharmaceuticals in a research note on Monday, September 9th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $32.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th.
Check Out Our Latest Stock Report on KALV
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
